DNA

Illumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base

 Accessible, highly scalable single-cell technology expands Illumina's multiomics capabilities SAN DIEGO, July 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a…

6 months ago

Organic & Natural Health Association Welcomes New President and Four New Board Members

Todd Norton Named Board President of O&N Health Todd Norton, the vice president of business development at Aker BioMarine, and…

6 months ago

GeneType to Enter Canadian and New Zealand Markets

Genomics-based testing brand expands international presence as pilot influencer campaign fuels salesCHARLOTTE, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- Genetic…

6 months ago

AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450

– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the…

6 months ago

Paragon Genomics Partners with Biosecure ID to Expand Access to CleanPlex® Technology in the UK and Ireland

--Follows A Half Dozen New Distributor Agreements Around the Globe for Paragon Genomics’ Unique CleanPlex® NGS Target Enrichment Technology--FREMONT, Calif.,…

6 months ago

Bio-Path Holdings Provides Clinical Update and Expansion Plans

Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for…

6 months ago

Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day

SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted…

6 months ago

Iktos acquires Synsight, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discovery

PRESS RELEASE Iktos acquires Synsight, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discovery Synsight provides…

6 months ago

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia…

6 months ago

Revolutionizing Precision Health with AI: SelfDecode Unveils Groundbreaking Precision Health GPT

MIAMI, July 3, 2024 /PRNewswire/ -- SelfDecode, a leader in personalized health and wellness, is proud to announce the launch…

6 months ago